Merck KGaA (MRK) - Total Assets
Based on the latest financial reports, Merck KGaA (MRK) holds total assets worth €50.93 Billion EUR (≈ $59.54 Billion USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See what is Merck KGaA's book value for net asset value and shareholders' equity analysis.
Merck KGaA - Total Assets Trend (2002–2024)
This chart illustrates how Merck KGaA's total assets have evolved over time, based on quarterly financial data.
Merck KGaA - Asset Composition Analysis
Current Asset Composition (December 2024)
Merck KGaA's total assets of €50.93 Billion consist of 26.1% current assets and 73.9% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 4.2% |
| Accounts Receivable | €4.08 Billion | 7.9% |
| Inventory | €4.48 Billion | 8.7% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €6.28 Billion | 12.2% |
| Goodwill | €19.15 Billion | 37.1% |
Asset Composition Trend (2002–2024)
This chart illustrates how Merck KGaA's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see MRK market cap overview.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Merck KGaA's current assets represent 26.1% of total assets in 2024, a decrease from 41.9% in 2002.
- Cash Position: Cash and equivalents constituted 4.2% of total assets in 2024, down from 4.5% in 2002.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 49.0% of total assets, an increase from 24.0% in 2002.
- Asset Diversification: The largest asset category is goodwill at 37.1% of total assets.
Merck KGaA Competitors by Total Assets
Key competitors of Merck KGaA based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Daihan Pharmaceutical Co.Ltd
KQ:023910
|
Korea | ₩344.02 Billion |
|
Aurobindo Pharma Limited
NSE:AUROPHARMA
|
India | Rs525.46 Billion |
|
China Resources Sanjiu Medical & Pharmaceutical Co Ltd
SHE:000999
|
China | CN¥56.56 Billion |
|
Ningbo Menovo Pharm Co Ltd
SHG:603538
|
China | CN¥4.75 Billion |
|
Zhejiang Xianju Pharmaceutical Co Ltd
SHE:002332
|
China | CN¥7.26 Billion |
|
Qianjiang Yongan Pharmaceutical Co Ltd
SHE:002365
|
China | CN¥2.26 Billion |
|
Zhejiang Cheng Yi Pharmaceutical Co Ltd
SHG:603811
|
China | CN¥1.69 Billion |
|
Hainan Honz Pharmaceutical Co
SHE:300086
|
China | CN¥1.88 Billion |
Merck KGaA - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.49 | 1.33 | 1.01 |
| Quick Ratio | 0.97 | 0.91 | 0.65 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €4.24 Billion | €3.47 Billion | €49.00 Million |
Merck KGaA - Advanced Valuation Insights
This section examines the relationship between Merck KGaA's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.92 |
| Latest Market Cap to Assets Ratio | 0.32 |
| Asset Growth Rate (YoY) | 6.3% |
| Total Assets | €51.57 Billion |
| Market Capitalization | $16.63 Billion USD |
Valuation Analysis
Below Book Valuation: The market values Merck KGaA's assets below their book value (0.32x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Merck KGaA's assets grew by 6.3% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Merck KGaA (2002–2024)
The table below shows the annual total assets of Merck KGaA from 2002 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | €51.57 Billion ≈ $60.29 Billion |
+6.33% |
| 2023-12-31 | €48.49 Billion ≈ $56.70 Billion |
-0.06% |
| 2022-12-31 | €48.53 Billion ≈ $56.73 Billion |
+6.98% |
| 2021-12-31 | €45.36 Billion ≈ $53.03 Billion |
+8.53% |
| 2020-12-31 | €41.80 Billion ≈ $48.86 Billion |
-4.60% |
| 2019-12-31 | €43.81 Billion ≈ $51.22 Billion |
+18.77% |
| 2018-12-31 | €36.89 Billion ≈ $43.13 Billion |
+3.56% |
| 2017-12-31 | €35.62 Billion ≈ $41.64 Billion |
-6.88% |
| 2016-12-31 | €38.25 Billion ≈ $44.72 Billion |
+0.64% |
| 2015-12-31 | €38.01 Billion ≈ $44.43 Billion |
+46.12% |
| 2014-12-31 | €26.01 Billion ≈ $30.41 Billion |
+24.94% |
| 2013-12-31 | €20.82 Billion ≈ $24.34 Billion |
-3.81% |
| 2012-12-31 | €21.64 Billion ≈ $25.30 Billion |
-2.16% |
| 2011-12-31 | €22.12 Billion ≈ $25.86 Billion |
-1.20% |
| 2010-12-31 | €22.39 Billion ≈ $26.17 Billion |
+33.96% |
| 2009-12-31 | €16.71 Billion ≈ $19.54 Billion |
+6.83% |
| 2008-12-31 | €15.64 Billion ≈ $18.29 Billion |
+4.84% |
| 2007-12-31 | €14.92 Billion ≈ $17.45 Billion |
+84.17% |
| 2006-12-31 | €8.10 Billion ≈ $9.47 Billion |
+11.29% |
| 2005-12-31 | €7.28 Billion ≈ $8.51 Billion |
+27.24% |
| 2004-12-31 | €5.72 Billion ≈ $6.69 Billion |
-18.05% |
| 2003-12-31 | €6.98 Billion ≈ $8.16 Billion |
-7.04% |
| 2002-12-31 | €7.51 Billion ≈ $8.78 Billion |
-- |
About Merck KGaA
Merck KGaA operates as a science and technology company in Germany and internationally. It operates through Life Science, Healthcare, and Electronics segments. The Life Science segment offers tools, chemicals, and equipment for academic labs, biotech, and pharmaceutical manufacturers, as well as the industrial sector. This segment offers science and lab solutions comprising reagents, consumables,… Read more